Psoriatic arthritis: Pathogenesis and novel immunomodulatory approaches to treatment
Sarah Cassell and Arthur Kavanaugh*

Address: Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, The University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0943, USA
Email: Sarah Cassell - scassell@ucsd.edu; Arthur Kavanaugh* - akavanaugh@ucsd.edu
* Corresponding author

Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy characterized by the association of arthritis and psoriasis. PsA runs a variable course, from mild synovitis to severe, progressive, erosive arthropathy. The pathogenesis of PsA involves alteration in the components of the immune response, although the exact cause of PsA is unknown. A number of patients with severe peripheral arthritis fail to respond to standard conventional therapy. Advances in biotechnology and in our understanding of the immunopathogenesis of PsA have led to great interest and progress in regards to biologic treatments for PsA. Notable success achieved with recently introduced biologic therapies has paved the way for further research and development of additional therapies that should improve outcomes for affected patients.

Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy characterized by the association of arthritis and psoriasis. Joint involvement is heterogeneous, and may consist of spondyloarthropathy, as well as oligoarticular and polyarticular peripheral arthritis. PsA runs a variable course, from mild synovitis to severe, progressive, erosive arthropathy. PsA is classified as one of the subtypes of spondyloarthropathy, sharing clinical features such as asymmetric joint involvement, an oligoarticular arthritis pattern, a similar frequency in men and women, the common occurrence of enthesitis and dactylitis, infrequent rheumatoid factor and anti-cyclic-citrullinated-peptide seropositivity, and extra-articular manifestations such as iritis.

Epidemiology
Psoriasis occurs in about 2% of the population [1]. PsA has been reported in 7% to 42% of patients with psoriasis [2]. The prevalence of PsA in the US has been estimated as 0.67% [3]. However, estimates of prevalence are variable, due in part to the heterogeneity of the disease as well as a lack of validated diagnostic criteria [4].

In general, skin involvement precedes joint disease, often by years. However, PsA precedes skin psoriasis in about 15% of patients, and the two occur simultaneously in about 20%. Some reports suggest that PsA is more common in patients with severe psoriasis [5,6]. A recent study suggested a correlation between the extent of skin and joint severity only among patients with simultaneous onset of skin and joint manifestations [7].
**Pathogenesis**

The exact cause of PsA is unknown, although genetic, environmental, and immunologic factors clearly play important roles. The pathogenic connection between psoriasis and arthritis is not clear, although both are immunologically mediated.

**Genetic factors**

Most studies document a familial predisposition to both psoriasis and PsA. More than 40% of patients with PsA have first degree family members with either skin or joint disease [8,9]. Several genetic susceptibility loci have been proposed, with the strongest effect residing within the major histocompatibility complex (MHC). Population studies in PsA have shown increased frequency of HLA-B13, B17, B27, B38, B39, DR4 and DR7 [8,10,11]. In a comparison of 158 patients with PsA to 101 patients with uncomplicated psoriasis, HLA-B7 and B27 were more common among patients with PsA, whereas B17, Cw6 and DR7 were more common among patients with uncomplicated psoriasis [8]. Some of these associations may be confounded by linkage disequilibrium. HLA-B27 has been associated with spinal disease in which radiologic sacroiliitis is present. A symmetric pattern of peripheral PsA appears related to HLA-DR4 [8,12]. The strongest susceptibility locus for psoriasis is on chromosome 6p, termed PSORS1 [1,13-16]. Other psoriasis susceptibility loci are located on chromosomes 17q25 (PSORS2), 4q34 (PSORS3), 1q (PSORS4), 3q21 (PSORS5), 19p13 (PSORS6), 1p (PSORS7), and 17q25 (RUNX1) [1].

Other genes within the MHC region and non-HLA associations have been explored. A TNF-α promoter polymorphism or a gene in linkage disequilibrium with TNF-α may predispose or increase susceptibility to psoriasis and PsA [17]. One study looking at the TNFβ+252 and TNFα-308 polymorphisms did not find the alleles more frequently in PsA patients than matched controls, but did find both alleles were significantly associated with the presence of joint erosions and the progression of joint erosions in early PsA [18]. A meta-analysis showed the TNFα-238 variant in Caucasian PsA patients was a significant risk factor for PsA [19]. A recent study pointed to Cw6 and MHC class I chain-related A (MICA)-A9 as being the strongest genetic susceptibility factors for PsA [20].

**Environmental factors – infection, trauma**

Both viral and bacterial infections have been implicated as causative agents in PsA. Support for the role of bacterial antigens in the pathogenesis of psoriasis and PsA comes from indirect observation of enhanced humoral and cellular immunity to gram-positive bacteria typically found in the psoriatic plaques [21]. However, psoriatic plaques often get secondarily infected, thus the cause-effect relationship of bacteria and psoriasis is difficult to prove. One study of sera from patients with PsA showed higher levels of antibody to streptococcal exotoxin, which provides some evidence of a link between streptococcal infection and articular inflammation [22]. The possibility that PsA might be virally induced has been proposed, although never confirmed [23,24]. Physical trauma may result in the onset of psoriasis (Koebner Phenomenon) and, theoretically, PsA at the sites of injury. This association would highlight potential association between innate and specific immunity. There are a number of case reports suggesting a possible role for trauma in PsA, but this has not been evaluated in a prospective manner.

**Immunologic factors**

Both psoriasis and PsA are immunologically mediated. Characteristic pathologic features of PsA are synovial lining layer cell hyperplasia, inflammatory cell accumulation and prominent vascularity. T lymphocytes, particularly CD8+ cells, may play important pathogenic roles. Activated T cells have been noted in affected tissue, both skin and joint [25,26]. A predominance of CD8+ T lymphocytes with clonal expansion have been found in PsA synovial fluid leading to the proposal that CD8+ T cells drive the immune response [27]. This is further supported by the fact that CD8+ T cells also dominate the infiltrate at marrow sites adjacent to enthesal inflammation, an early area of involvement [28]. An analysis of T cell receptor beta chain variable (TCRβV) gene repertoires revealed common expansions in both skin and synovial inflammatory sites, suggesting an important role for cognate T cell responses in the pathogenesis of PsA and that the inciting antigen may be identical or homologous between afflicted skin and synovium [29].

The cytokine network in the psoriatic skin and synovium is dominated by monocyte and T-cell derived cytokines: IL-1β, IL-2, IL-10, IFN-γ and TNF-α [30]. In PsA synovium, higher levels of IFN-γ, IL-2 and IL-10 have been detected than in psoriatic skin. One study of cytokine staining in PsA synovium showed IL-1α, IL-1β, IL-8, IL-15, IFN-γ and TNF-α staining localized to the lining layer and perivascular macrophages [31]. These cytokines can induce proliferation and activation of synovial and epidermal fibroblasts, leading to fibrosis in patients with longstanding PsA. TNF-α, a key proinflammatory cytokine, induces the production of other inflammatory cytokines such as IL-1, IL-6, and granulocyte-macrophage colony-stimulating factor, chemokines such as IL-6, degradative enzymes such as several matrix metalloproteinases (MMPs) and other factors. TNF-α mediates a number of biological processes that can result in joint damage including stimulation of bone resorption, inhibition of bone formation, and inhibition of synthesis of proteoglycans [32,33]. Angiogenic factors such as TNF-α and vascular endothelial
growth factor (VEGF) may contribute to vascular proliferation [34,35].

While the mechanisms governing psoriatic skin and joint involvement are similar, there are distinctions. For example, cutaneous lymphocyte associated (CLA) antigen, an adhesion molecule that identifies lymphocytes that preferentially traffic to the skin, is upregulated on lymphocytes in psoriatic skin but is minimally expressed on cells in the PsA synovium [36].

**Clinical Features**

Wright and Moll recognized several patterns of PsA: isolated distal interphalangeal disease, peripheral oligoarthritis, peripheral polyarthritis, and spondyloarthropathy. These clinical phenotypes are not fixed but are interchangeable, and individual patients can switch phenotypes [37]. The most important distinction as regards outcome appears to be oligo- versus poly-articular joint involvement.

Extra-articular manifestations of PsA are important aspects of the disease, the most common is the psoriatic skin lesion, which may affect all areas of the skin. Dactylitis is typical in PsA and presents as inflammation of the whole digit, joints and tendon sheaths. Enthesitis, inflammation at the site of tendon, ligament or synovial membrane insertion into bone, is characteristic of PsA and may represent the earliest site of involvement. Other extra-articular manifestations include the presence of iritis, mouth ulcers, and urethritis.

PsA has several characteristic radiographic features which include lack of periarticular osteopenia, destruction of interphalangeal joints with widening of the joint spaces, pencil-in-cup changes in the hands and feet, ankylosis, periosteal reaction, and spur formation [38].

The course of PsA is variable. Patients who have five or more involved joints at presentation are more likely to have progressive disease. Some patients have few episodes and completely recover, but recent studies demonstrated that many patients have persistent and severe courses [39-41]. Damage in PsA occurs early and progresses over time, with increasing deformities and limitation of daily activity [42]. Patients with PsA have increased mortality compared to the general population. More severe disease, as manifested by higher ESR and radiologic scores at presentation, is a predictive factor of mortality [43].

**Treatment of PsA**

**Conventional treatment**

Mild joint symptoms may respond to non-steroidal anti-inflammatory drugs (NSAIDs) [42]. Systemic steroids can be used, but may cause side effects and rebound worsening of psoriasis [44]. Patients who are unresponsive to NSAID therapy or who have progressive disease may require disease modifying anti-rheumatic drugs (DMARDs) (eg methotrexate [MTX], leflunomide, sulfasalazine [SSZ], cyclosporine [CsA]).

MTX is considered by many rheumatologists the DMARD of choice because of its remarkable efficacy in ameliorating both skin and joint disease, its rapid onset, and its acceptable safety profile [45,46]. However, 16–30% of patients treated with MTX discontinue it because of toxicity [47,48]. Leflunomide, an antipyrимidine drug that interferes with T-cell activation, has been shown to be effective in improving both joint and skin symptoms [49]. The most common side effects seen with leflunomide are diarrhea and increased transaminases. SSZ has been shown to be helpful for peripheral arthritis but not for axial disease [50]. CSA improves both joint inflammation and skin lesions in PsA, but is not frequently used because of its toxicities, the most worrisome being hypertension and nephrotoxicity [48,51]. Likewise, gold compounds and other drugs have been reported to ameliorate arthritis in some PsA patients, but are rarely used secondary to side effects and toxicities.

**Biologic Agents**

In recent years, greater understanding of immunopathology and advances in biotechnology facilitating the ability to design and produce novel biologic agents have led to exciting breakthroughs in the treatment of autoimmune disease, including psoriasis and PsA [52]. The development of novel biologic agents has been further encouraged by the unmet need for better treatments and the positive results with their use in other autoimmune diseases, particularly rheumatoid arthritis (RA). The most significant experience of the use of biologics in treatment of PsA is with TNF-α inhibitors.

**Tumor necrosis factor-alpha (TNF-α) inhibitors**

Given its pro-inflammatory potential and its elevated levels in RA and PsA, TNF-α was identified as an attractive target for biologic therapies. TNF-α inhibitors have been used with great success to suppress joint inflammation in RA, inducing not only marked improvement in the signs and symptoms of disease, but also substantially improved functional status and quality of life [53-55]. Additionally, they have been shown to attenuate the progression of radiographic joint damage. Adverse effects have been reported, but in general these agents are well-tolerated. These encouraging results spurred interest in using TNF-α inhibitors in PsA. Currently there are three TNF-α inhibitors available: 1) etanercept, a fusion protein consisting of a dimer of the extracellular portion of the type II TNF receptor (p75) linked to the Fc portion of IgG1, 2) infliximab, a chimeric monoclonal antibody specific for TNF-α,
and 3) adalimumab, a human monoclonal antibody specific for TNF-\(\alpha\).

1. **Etanercept**

Etanercept has been proven effective for the treatment of PsA [56,57]. The first double-blind, placebo controlled clinical trial of etanercept in PsA was in 60 patients with long-standing disease. The etanercept group showed significant improvement in all measures of disease activity compared with the placebo group at 12 weeks. The primary endpoint for arthritis activity, the Psoriatic Arthritis Response Criteria (PsARC), a composite index, was achieved by 87% versus 23% of the etanercept and placebo groups respectively [58]. A secondary endpoint was the American College of Rheumatology composite response criteria (ACR), a score based on 20%, 50%, or 70% improvement [59]. ACR20 responses were 73% and 13% in the etanercept and placebo groups respectively [56]. For psoriasis, the primary endpoint was 75% improvement in the Psoriasis Area and Severity (PASI) score (PASI75). Of patients with >3% body surface involvement, 26% of etanercept treated patients achieved PASI75 versus none in the placebo treated group [56]. Disability, as assessed by responses on the health assessment questionnaire (HAQ), significantly improved in the etanercept group. An open-label extension of this study revealed sustained efficacy in joints, further improvement of skin disease, ability to decrease or discontinue concomitant methotrexate and prednisone, and continued tolerability [60].

Another phase III clinical trial of etanercept in 205 patients with PsA confirmed and extended earlier findings. ACR20 response rates were achieved by 59% of the etanercept group and 15% of the placebo group at 12 weeks (P < 0.001). This clinical response was sustained for 24 weeks. Of those meeting criteria for PASI evaluation, the etanercept group showed on average 47% improvement compared to no improvement in the placebo group (P < 0.001) [57].

Etanercept has been observed to slow and halt radiographic structural damage in PsA. A one year study of 205 patients revealed that at twelve months the radiographic disease progression in the etanercept group was inhibited (Sharp score: -0.03 units) compared with worsening in the placebo group (Sharp score: +1.00 units) (p = .0001) [61].

2. **Infliximab**

Open-label studies of infliximab in PsA showed significant decreases in the signs and symptoms of joint inflammation and skin disease [62-64]. This led to double blind, placebo controlled trials, which also revealed positive results [65,66]. The infliximab multinational psoriatic arthritis controlled trial (IMPACT) enrolled 104 patients in a double blind, randomized, placebo-controlled trial for 16 weeks, followed by blinded single-crossover design through 50 weeks [65]. ACR20/50/70 responses at week 16 were 69%/49%/29% in the active treatment group compared to 8%/0%/0% in the placebo group. These results were sustained at 50 weeks with ACR 20/50/70 responses in the infliximab group of 72%/54%/35%. Of the placebo-treated patients who crossed over to active treatment at week 16, ACR20/50/70 responses increased to 77%/49%/30%. This study also assessed dactylitis and enthesitis, two important characteristics of PsA that had not previously been included in clinical trials. Significant improvements were seen in dactylitis and enthesitis with infliximab therapy. Of particular note in this study was the dramatic improvement in skin psoriasis seen with infliximab treatment. Thus, PASI75 was achieved by 12 of 14 infliximab patients whereas there was overall worsening of skin scores in the placebo treated group. This effect was sustained at week 50. Also, 8 of 16 placebo patients who switched to infliximab treatment after week 16 achieved PASI75 at week 50.

These results were confirmed with the subsequent larger phase 3 IMPACT 2 study [67]. In this trial, 200 patients with active PsA were randomized to receive infliximab or placebo for 24 weeks. ACR 20/50/70 scores at week 24 in the infliximab group were 54%/41%/27% and 11%/4%/2% in the placebo group. Again, skin improvement was very impressive, with 60% of the infliximab group achieving PASI75 at week 24, whereas only 1% of the placebo group did. Statistically significant improvements in measures of functional status and quality of life (measured by HAQ and SF-36, respectively) were seen, as were improvements in dactylitis and enthesopathy.

Two studies have shown that infliximab can inhibit radiographic disease progression. In a double-blind, placebo controlled trial of 200 PsA patients (IMPACT2), patients treated with infliximab had significantly less radiographic disease progression at week 24, as measured by the van der Heijde-Sharp method modified for PsA (-0.7 +/- 2.53 versus 0.82 +/- 2.62, for infliximab versus placebo treated patients respectively; p < 0.001) [68]. An analysis of patients from the IMPACT1 study showed that at 50 weeks, radiographic progression of disease was inhibited in both the group treated with infliximab throughout the trial as well as in the group receiving infliximab from week 16 through week 50 [69].

3. **Adalimumab**

Adalimumab was assessed in PsA in a phase III, placebo-controlled, double blind study, the Adalimumab Effectiveness in PsA Trial (ADEPT) [70]. 151 patient received adalimumab and 162 received placebo. Adalimumab treated patients showed rapid improvements. At week 24
ACR20, 50, and 70 scores for adalimumab were 57%, 39%, and 23% respectively versus 15%, 6%, and 1% for placebo. PASI50, 75 and 90 scores for adalimumab and placebo respectively were 75%, 59%, and 42% versus 12%, 1%, and 0% [70].

Adalimumab was also shown to inhibit radiographic disease progression. In the ADEPT trial, at week 24 mean change in modified total Sharp Scores (mTSS) was -0.2 in infliximab treated patients compared with +1.0 in placebo treated patients (p <= .001). All patients were allowed to go into an open label extension after week 24. Patients who started in the placebo arm and crossed to the adalimumab open label arm at week 24 had mTSS scores of +1.0 and +1.0 at weeks 24 and 48 respectively, showing no further radiographic progression after they started adalimumab. The patients originally in the adalimumab arm who extended into open label treatment had mTSS scores of -0.2 and 0.1 at weeks 24 and 48 respectively. Assessments at week 48 showed that adalimumab maintained the lack of radiographic change [71].

With all TNF-α inhibitors there have been concerns about safety issues, particularly infections, serious infections and opportunistic infections such as reactivation of latent tuberculosis. Appropriate monitoring for signs and symptoms of infection is required before and during treatment. While other adverse events have been reported at relatively low rates, careful monitoring of patients on these new biologic agents is quite important.

Alefacept
Another biologic agent in development for PsA is alefacept, which was approved in the US for the treatment of psoriasis in 2003. Alefacept is a human LFA-3/IgG1 fusion protein and is under clinical investigation for the treatment of PsA and RA. The LFA-3 portion of alefacept binds to CD2 receptors on T cells to block the natural interaction between LFA-3 on antigen-presenting cells and CD2 on T cells. Blockade of the LFA-3/CD2 interaction, a key co-stimulatory pathway, can inhibit T-cell activation. The IgG1 portion of alefacept can bind to FcγRIII (CD16) IgG receptors on accessory cells (e.g. natural killer cells) and may induce granzyme-mediated apoptosis [52,72].

Alefacept was evaluated as a treatment for psoriasis in a multicenter, randomized, placebo-controlled, double blind study. Two hundred twenty-nine patients with chronic psoriasis received intravenous injection of alefacept at different dosages. The mean reduction in the PASI score 12 weeks after treatment was greater in the alefacept groups than the placebo group [73].

A small study suggested that alefacept may also improve both skin and joint symptoms in PsA [74]. In a single center open-label study, 11 patients with PsA received intravenous 7.5 mg alefacept once weekly for 12 weeks. Synovial tissue biopsies of an index joint were obtained by arthroscopy at baseline and at weeks 4 and 12. Clinically, some degree of improvement in arthritis was observed in six patients (55%) at the completion of the treatment. A similar proportion of patients achieved 50% amelioration of skin disease. This study supports the notion that T cell activation plays an important role in chronic inflammatory diseases and effective blockade of the LFA-3/CD2 interaction may be useful for treating PsA.

Additionally, a double blind, placebo controlled trial assessed the combination of alefacept and methotrexate in 185 PsA patients. An ACR20 response was achieved by 54% of the alefacept group versus 24% of the placebo group. 53% of the alefacept group achieved PASI50 compared with 17% of the placebo group [75]. Adverse events in this trial occurring at >5% included: back pain, nasopharyngitis, nausea, URI and increased ALT. There were no serious infections and the serious adverse event rate was 2% [76].

Efalizumab
Leukocyte function associate antigen-1 (LFA-1) is an adhesion molecule expressed on T lymphocytes. It interacts with its ligand, intercellular adhesion molecule (ICAM-1), in ways that may be relevant to the pathogenesis of psoriasis including: stabilizing the binding of antigen-presenting cells to T lymphocytes, facilitating migration of T lymphocytes from circulation into skin, and activation of T lymphocytes [77]. Efalizumab is a humanized monoclonal IgG antibody that binds to the alpha-subunit (CD11) of LFA-1 and prevents LFA-1 binding to ICAM-1. In two recent phase 3, randomized, double-blind, placebo-controlled trials, efalizumab showed efficacy in treating moderate to severe plaque psoriasis, and was recently approved for this use by the US FDA.

Leonardi et al, reported a study of 498 psoriasis patients that showed PASI75 scores at 12 weeks in the treatment groups were achieved in 32.6% of patients versus 2.4% of placebo-treated patients [77]. The most common adverse events (headache, fever, chills, nausea, and myalgias) were more frequent in the efalizumab-treated group only during the first two injections, and then decreased to rates similar to placebo. A second study randomized 556 psoriasis patients for twelve weeks with continuation in an open label study [78]. At 12 weeks, PASI50/75 were 58.5%/26.6% respectively in efalizumab-treated patients compared with 13.9%/4.3% in placebo treated patients. These numbers increased at week 24. Patient reported outcomes (dermatology life quality index and itching scale) also improved. Interestingly, during the second twelve weeks there was an increased incidence of arthritis.
of potential importance in the pathogenesis of joint and other inflammation [82]. Anakinra (IL-1ra) a homologue of the naturally occurring IL-1 receptor antagonist, has been approved for use in moderate to severely active RA. Other IL-1 inhibiting agents are in development. To date there have not been controlled clinical trials of IL-1 inhibitors in PsA.

Another approach that would suppress inflammation involves the therapeutic use of anti-inflammatory cytokines. For example, among its various activities, IL-10 inhibits INF-γ and promotes TH2 biased cytokine secretion. IL-10 is relatively deficient in psoriatic skin, although it is found in high levels in synovium and serum of PsA patients [83]. Recombinant IL-10 (rIL-10) was used in a phase II trial in 14 patients with chronic plaque psoriasis; 71% had more than a 50% reduction of PASI scores [84]. It has also been studied in PsA which showed modest improvements in skin but not articular disease [85]. Recombinant human IL-11 (rhlL-11) has been shown to have anti-inflammatory activity in vitro and in vivo and has been tested in 12 patients with psoriasis. They showed some improvement in PASI scores [86]. However, there are no published reports of it being used in PsA.

Another therapeutic strategy is to target the number or function of immunocompetent cells central to the propagation of the disease. Several therapies have targeted T cells, which have been suggested to play a central role in orchestrating the immune driven inflammation in PsA. Daclizumab, a humanized antibody to the α-subunit of the IL-2 receptor, blocks the binding of IL-2, a vital growth

### Table 1: Biologic agents under consideration for the treatment of Psoriatic arthritis

| Suppression of inflammatory mediators | Modulation of the function of Anti-inflammatory mediators | Alteration of T cell number and function interaction |
|-----------------|-----------------|-----------------|
| **target** | **agent** | **comment** | **target** | **agent** | **comment** | **target** | **agent** | **comment** |
| IL-1 | Anakinra | IL-1 receptor antagonist | IL-10 | rIL-10 | recombinant human Th2 cytokine |
| IL-8 | ABXIL-8 | human anti-IL-8 mAb | IL-11 | rIL-11 | recombinant human Th2 cytokine |
| IL-12 | anti-IL-12 mAb | several in development | CD25 (IL-2 receptor) | Daclizumab | humanized anti-CD25 mAb |
| CD2 | Alefacept | human LFA-3IgG fusion protein | CD11a (LFA-1) | Efailizumab | humanized anti-CD11a mAb |
| CD80/CD86 | IDEC-114 | humanized anti-CD80 mAb | CD40/CD40L | IDEC-131 | fusion protein of CTLA-4Ig |
| mAb, monoclonal antibody; rIL, recombinant interleukin; IL-2R, LFA, leukocyte function associated antigen; TCR, T-cell receptor; CTLA4Ig, cytotoxic T-lymphocyte-associated antigen 4/IgG1

(5.6%); 12 of these 19 cases had had a prior history of arthritis.

Preliminary results from a phase II study of efalizumab in 117 PsA patients showed that treatment did not reach statistical significance as far as achieving an ACR20 reponse at twelve weeks [79].

**Other types of biologic agents and future directions**

The introduction of TNF-α inhibitors and their tremendous clinical impact has generated considerable interest in exploring other avenues for the treatment of PsA. In addition, it is worth noting that despite the tremendous success achieved in PsA patients treated with TNF-α inhibitors, approximately one-third of patients with moderate to severe PsA have negligible or insufficient responses to such treatment. This has provided the impetus for the development of biologic agents targeting other aspects of the dysregulated immune system. Several promising biologic agents, directed at targets other than TNF-α, are currently under study (Table 1).

One approach is the targeting of other inflammatory mediators. ABXIL-8 (Abgenix Inc, Fremont, CA), a human anti-IL-8 monoclonal antibody, binds free IL-8 and may deactivate it in the skin. Effects of IL-8 include T cell and neutrophil activation and chemotaxis, as well as keratinocyte proliferation. IL-8 may also play a role in the vascular responses found in psoriasis [80]. A phase II trial in psoriasis showed some improvement in patients’ PASI as well as in histological responses [81]. IL-1, many of the activities of which overlap with TNF, has been suggested to be
factor for T cells. One trial in 19 psoriatic patients showed IL-2 blockade during the first 4 weeks and variable desaturation after that, which correlated with reversal in disease improvement that had been achieved. Patients with pretreatment PASI score of <36 showed mean reduction in severity by 30% at eight weeks [87]. HuOKT3γ1 (ala-ala), a non-FcR-binding monoclonal antibody to CD3 (a component of the T cell receptor complex), modulates the function of T cells without decreasing their numbers. A phase I/II study in seven patients with PsA showed 6/7 achieving ACR70 responses at 30 days and all seven had transient, dose dependent depletion of T cells [88]. CD28 is a cell-surface protein on mature T cells and binds to two ligands, CD80 and CD86 on antigen-presenting cells. Blocking this interaction results in incomplete T cell activation. CTLA-4, a natural inhibitor of CD28, binds to CD80/86 molecules with high affinity and competes with CD28. CTLA-4-immunoglobulin (CTLA-4Ig) was developed to block the CD 28 and CD80/86 interactions. A phase 1 trial in psoriasis patients showed dose dependent improvement in skin involvement [89]. A CTLA-4-Ig construct, abatacept, is in late phase development for the treatment of RA. It will likely be studied in PsA in the near future. IDEC-114, a humanized anti-CD80 monoclonal antibody, has also been developed to block this interaction. A phase I/II trial of IDEC-114 in 35 psoriatic patients showed 40% of patients achieved PASI50 [90]. Finally, therapies directed at inhibiting IL-12, a cytokine central in driving Th1 biased immune responses, are in the early phases of investigation in psoriasis and PsA.

Conclusion
Appreciation of the unmet clinical need for affected patients, greater understanding of the underlying immunopathophysiology of this common autoimmune disease, and progress in biopharmaceutical development have paved the way for the development of novel biologic agents for PsA. Following closely upon the successes achieved in RA, there have been dramatic clinical efficacy achieved with TNF inhibitors. Substantial improvements have been noted not only as far as the signs and symptoms of arthritis, but also in dactylitis and enthesitis and in skin involvement. Moreover, improvements in functional status and quality of life, and attenuation in the progression of radiographic damage have been achieved. Driven by this success, biologic agents targeting other components of the dysregulated immune response that play major roles in pathogenesis of PsA are actively under study. In the foreseeable future, we can expect further exciting development in immunomodulatory therapies for psoriatic arthritis.

References
1. Schon M, Boekkno WH: *Psoriasis*. NEJM 2005, 352:1899-1912.
2. Gladman DD: *Psoriatic arthritis*. Rheum Dis Clin North Am 1998, 24:829-44.
3. Lawrence RC, Hochberg MC, Kelsey JL, et al: *Estimate of the prevalence of selected arthritis and musculoskeletal diseases in the United States*. J Rheumatol 1998, 25:1440-1445.
4. Gladman DD, Farewell VT, Nadeau C: *Clinical indicators of progression in psoriatic arthritis: multivariate relative risk mode*. J Rheumatol 1995, 22:675-9.
5. Little H, Harvie JN, Lester RS: *Psoriatic arthritis in severe psoriasis*. Can Med Assoc J 1975, 112:317-9.
6. Leonard DG, O’Duffy JD, Rogers RS: *Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis*. Mayo Clin Proc 1978, 53:511-8.
7. Elkayam O, Ophir J, Yaron M, Caspi D: *Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course, and distribution*. Clin Rheumatol 2000, 19:301-5.
8. Gladman DD, Anhorn KAB, Schachtner RK, Mervart H: *HLA antigens in psoriatic arthritis*. J Rheumatol 1986, 13:586-92.
9. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachtier RK: *Psoriatic arthritis – an analysis of 220 patients*. Quart J Med 1987, 62:127-41.
10. Espinoza LR: *Psoriatic arthritis: further epidemiologic and genetic consideration*. In *Psoriatic arthritis* Edited by: Gerber LH, Espinoza. Grune & Stratton, Orlando Florida; 1985:9-32.
11. Sales LJ, Loqueman O, Bavin RA, Naugham RW, Welsh KJ, Panayi GS: *HLA class II and T cell receptor gene polymorphisms in psoriatic arthritis and psoriasis*. J Rheumatol 1990, 17:1487-90.
12. Eastmon CJ: *Psoriatic arthritis. Genetics and HLA antigens*. Bailleres Clin Rheumatol 1994, 8:263-76.
13. Tomfohrde J, Silverman A, Barnes R, et al: *Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q*. Science 1994, 264:1-115.
14. Matthews D, Fry L, Powels A, et al: *Evidence that a locus for familial psoriasis maps to chromosome 4q*. Nat Genet 1996, 13:221-3.
15. Burden A, Javed S, Bailey M, et al: *Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p*. J Invest Dermatol 1998, 110:58-60.
16. Veal CD, Clough RL, Barber RC, et al: *Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci*. J Med Genet 2001, 38:7-13.
17. Hohler T, Krugcr A, Schneider PM, et al: *A TNF-α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis*. J Invest Dermatol 1997, 109:562-5.
18. Balding J, Kane D, Lingston W, Mynett-Johnson L, Brensihan B, Smith O, FitzGerald O: *Cytokine Gene Polymorphisms: Associations with Psoriatic Arthritis Susceptibility and Severity*. Arthritis & Rheum 2003, 48:1408-1413.
19. Rahman P, Siannis F, Butt C, Farewell V, Peddle L, Pellet F, Gladman D: *Meta-Analysis of TNF-Alpha Polymorphisms in Caucasian Psoriatic Arthritis Populations*. Ann Rheum Dis 2005, 64(SII):325.
20. Gonzalez S, Martinez-Borra J, Lopez-Vazquez A, et al: *MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis*. J Rheumatol 2002, 29:973-8.
21. Vasey FB: *Etiology and pathogenesis of psoriatic arthritis*. In *Psoriatic arthritis* Edited by: Gerber LH, Espinoza. Grune & Stratton, Orlando Florida; 1985:45-57.
22. Vasey FB, Deitz C, Fenske NA, et al: *Possible involvement of group A streptococci in the pathogenesis of psoriatic arthritis*. J Rheumatol 1982, 9:719-22.
23. Njobvu P, McGill P: *Psoriatic arthritis and human immunodeficiency virus infection in the family*. J Rheumatol 2000, 27:1699-702.
24. Taglione EV, Martini ML, Galluzzo P, et al: *Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis*. J Rheumatol 1999, 26:370-2.
25. Panayi GS: *Immunology of psoriasis and psoriatic arthritis*. Bailleres Clin Rheumatol 1994, 8:419-27.
26. Veale DJ, Barnes L, Rogers S, Fitzgerald O: *Immunohistochemical markers for arthritis in psoriasis*. Ann Rheum Dis 1994, 53:450-4.
27. Costello PJ, Winchester RJ, Curran SA, et al: *Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clone expansions that appear antigen driven*. J Immunol 2001, 166:2878-86.
28. Laloux L, Voisin MC, Allain J, et al: *Immunohistological study of enthesis in spondyloarthopathies: comparison in rheumatoid arthritis and osteoarthritis*. Ann Rheum Dis 2001, 60:3-16-21.
29. Tassilius I, Duncan SR, Centola M, et al.: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. *Arthritis Immunol Rheum* 2009, 55:79-91.
30. Ritchlin C, Haas-Smith SA, Hicks D, et al.: Patterns of cytokine production in psoriatic synovium. *J Rheumatol* 1998, 25:1544-52.
31. Danning CL, Illie GG, Hitchon C, et al.: Macrophage-derived cytokine and nuclear factor kappa B p65 expression in synovial membranes and skin of patients with psoriatic arthritis. *Arthritis Rheum* 2000, 43:1244-56.
32. Saklatvala J: Tumor necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. *Nature* 1986, 322:547-9.
33. Bertolini DF, Willin GE, Bringman TS, et al.: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. *Nature* 1986, 319:516-8.
34. Ettedadi P, Greaves MW, Wallach D, et al.: Elevated tumor necrosis factor alpha biological activity in psoriatic skin lesions. *Clin Exp Dermatol* 2002, 27:275-81.
35. Fearon U, Reece R, Smith J, et al.: Synovial cytokine and growth factor regulation of MPPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. *Ann N Y Acad Sci* 1999, 878:619-21.
36. Ruland CA, Pirotte N, et al.: Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. *Arthritis Rheum* 1996, 39:137-45.
37. McHugh NJ, Balachrishnan C, Jones SM: Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. *Rheumatology* 2003, 42:778-83.
38. Resnick D, Niwayama G: Psoriatic arthritis. In *Diagnosis of bone joint disorders* WB Saunders Co, Philadelphia; 1981:1103-29.
39. Gladman DD, Shuckett R, Russell ML, et al.: Psoriatic arthritis – an analysis of 220 patients. *Quart J Med* 1987, 82:1-71.
40. Jones SM, Armas JB, Cohen MG, et al.: Psoriatic arthritis: Outcome of disease subsets and relationship of joint disease to nail and skin disease. *Br J Rheumatol* 1994, 33:834-9.
41. Kane D, Stafford L, Bresnihan B, Fitzgerald C: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. *Rheumatology* in press. 2003 Oct 1.
42. Pringle F: A multidisciplinary approach to psoriatic arthropathy. *Community Nurse* 1999, 5:21-2.
43. Gladman DD, Farewell VT, Wong K, Husted J: Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. *Arthritis Rheum* 1998, 41:1103-10.
44. Christophers E, Mrwowerz U: Psoriasis. In Fitzpatrick’s Dermatology in General Medicine 5th edition. Edited by: Freedberg IM, Eisen AZ, Wolff K, McGraw Hill, New York; 1999:495-521.
45. Black RL, O’Brian WM, Van Scott EJ, et al.: Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. *JAMA* 1964, 189:141-5.
46. Williksen RF, Neldams HJ, Ward JR, et al.: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. *Arthritis Rheum* 1984, 27:376-81.
47. Marquenie L, Filipo RM, Grardel B, et al.: Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. *Joint Bone Spine* 2002, 69:275-81.
48. Spadaro A, Taccari E, Motta D, et al.: Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs. *Clin Exp Rheumatol* 1997, 15:609-14.
49. Kaarttinen JP, Wallin I, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk F, Mease P, for the Treatment of Psoriatic Arthritis Study Group: Efficacy and Safety of Leflunomide in the Treatment of Psoriatic Arthritis and Psoriasis: A Multinational, Double Blind, Randomized Placebo Controlled Clinical Trial. *Arthritis Rheum* 2004, 50:1939-50.
50. Clegg DO, Reda DJ, Mejias E, et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. *A Department of Veterans Affairs Cooperatives Study. Arthritis Rheum* 1996, 39:2013-20.
51. Ellis CN, Fradin MS, Messana JM, et al.: Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. *N Engl J Med* 1991, 324:277-84.
52. Braun J, Sieper J: Role of novel biological therapies in psoriatic arthritis. *Biodrugs* 2003, 17:187-99.
53. Kavanaugh A, Cohen S, Cush J: The evolving use of TNF inhibitors in rheumatoid arthritis. *J Rheumatol* 2004, 31:1881-4.
54. Rowlings LW, Cohen SB, Baumgartner SW, et al.: Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. *J Rheumatol* 2001, 28:1238-44.
55. Bondeos J, Maini RN: Tumor necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMCICADE). *Int J Clin Pract* 2001, 55:211-16.
56. Mease P, Goffe BS, Metz J, et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized study. *Lancet* 2000, 356:385-90.
57. Mease P, Kivitz A, Burch F, et al.: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial (abstract). *Arthritis Rheum* 2001, 44(suppl 9):s90.
58. Clegg DO, Reda DJ, Mejias E, et al.: Comparison of sulfasalazine analagel in the treatment of psoriatic arthritis. *Arthritis Rheum* 1996, 39:2013-20.
59. Felson DT, Andersen JH, Boers M, et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995, 38:727-35.
60. Mease P, Goffe BS, Metz J, et al.: Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis (poster). *Ann Rheum Dis* 2001, 60(Suppl 1):i146.
61. Salvarani C, Cantini F, Olivieri I, et al.: Efficacy of infliximab in resistant psoriatic arthritis. *Arthritis Rheum* 2003, 49:341-5.
62. Olgivie AL, Antoni C, Dechant C, et al.: Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clearly shows skin lesions of psoriasis resistant to treatment with methotrexate. *Br J Dermatol* 2001, 144:587-9.
63. Van den Bosch F, Kruithof E, Baeten D, et al.: Effects of a loading dose regimen of three infusions of chimeric monoclonal anti-body to tumor necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. *Ann Rheum Dis* 2000, 59:428-33.
64. Antoni C, Kavanaugh A, Kirkham B, et al.: The one-year results of the infliximab multinational psoriatic arthritis controlled trial. *Arthritis Rheum* 2003, 49(suppl 9):S604.
65. Van den Bosch F, Kruithof E, Baeten D, et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. *Arthritis Rheum* 2002, 46:755-63.
66. van der Heijde DM, Krueger KE, De Vos, Birbara, Beutler, Guzzo, Zhou, Doolley J, Kavanaugh J: Infliximab Improves Signs and Symptoms of Psoriatic Arthritis: Results of the IMPACT 2 Trial. *Ann Rheum Dis* 2005, 64(S11):109.
67. Antoni C, Kavanaugh A, Gladman D, Wassenberg S, Zhou B, Dooley L, Antoni CE, Krueger GG, Gladman D: Infliximab Inhibits Progression of Radiographic Damage in Patients With Active Psoriatic Arthritis: Results for Impact 2 Trial. *Ann Rheum Dis* 2005, 64(S11):107.
68. Mease P, Gladman D, Ritchlin C, Ruderman E, Steinfeld S, Choy E, Perdok R, Weinberg M: Adalimumab Therapy in Patients with Psoriatic Arthritis: 24-week Results of a Phase III Study. *Arthritis Rheum* 2005, 52:2645-55.
69. Mease P, Sharp JI, Ory P, Gladman DD, Ritchlin CT, Choy EH, Weinberg EH: Adalimumab Treatment Effects on Radiographic Progression of Joint Disease in Patients with Psoriatic Arthritis: Result from ADEPT. *Ann Rheum Dis* 2005, 64(S11):320.
70. Weinberg JM: An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. *Clin Ther* 2003, 25:2487-505.
71. Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. *N Engl J Med* 2001, 345:248-55.
72. Kraan MC, van Kuik AJWR, Dinant HJ, et al.: Alefacept treatment in psoriatic arthritis. Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with
improvement of clinical signs of arthritis. Arthritis Rheum 2002, 46:2776-84.

75. Mease P, Gladman D, Keystone E: Efficacy of Alefacept in Combination with Methotrexate in the Treatment of Psoriatic Arthritis. Ann Rheum Dis 2005, 64(SII):324.

76. Gladman D, Mease P, Keystone E: Safety of Alefacept in Combination with Methotrexate in the Treatment of Psoriatic Arthritis. Ann Rheum Dis 2005, 64(SII):324-325.

77. Leonard, Papp, Gordon, Menter, Feldman, Cato, Walicke, Compton, Gottlieb: Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005, 52:425-433.

78. Menter, Gordon, Carey, Hamilton, Glazer, Caro, Li, Gulliver: Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients with Moderate to Severe Plaque Psoriasis. Arch Dermatol 2005, 141:31-38.

79. [http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=7287]

80. Barker JN, Jones ML, Mitor RS, et al.: Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol 1991, 139:869-876.

81. Singh P, West DP, Gordon KB: Patterns of cytokine production in psoriatic synovium. Arch Dermatol 2002, 138:657-663.

82. Bresnihan B, Cunnane G: Interleukin-1 receptor antagonist. Rheum Dis Clin North Am 1998, 24:187-199.

83. Ritchlin C, Haas-Smith SA, Hicks D, et al.: Patterns of cytokine production in psoriatic synovium. J Rheum 1998, 25:1544-1552.

84. Reich K, Garbe C, Blaschke V, et al.: Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 2001, 116:319-329.

85. McInnes IB, Illei GG, Danning CL, et al.: IL-10 Improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 2001, 167:2161-2168.

86. Trepicchio WL, Ozawa M, Walter IB, et al.: Interleukin-1 therapy selectively downregulates type 1 cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999, 104:1527-1537.

87. Krueger JG, Walters IB, Miyazawa M, et al.: Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000, 43:448-458.

88. Utset TO, Auger JA, Peace D, et al.: Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheum 2002, 29:1907-1913.

89. Abrams JR, Kelley SL, Hayes E, et al.: Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-Immunoglobulin (CTLA4lg) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000, 192:681-693.

90. Gottlieb A, Kang S, Linden K, Lebwohl M, Menter A, Abdulghani A, Goldfrab M, Cheiffo N, Tortoritis: Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Imm 2004, 111:28-37.